

B G Feagan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5704806/publications.pdf>

Version: 2024-02-01

369
papers

60,728
citations

1877

105
h-index

1117

238
g-index

446
all docs

446
docs citations

446
times ranked

21808
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. <i>Lancet, The</i> , 2002, 359, 1541-1549.	6.3	3,835
2	Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2005, 353, 2462-2476.	13.9	3,500
3	Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2013, 369, 699-710.	13.9	2,114
4	Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. <i>New England Journal of Medicine</i> , 2004, 350, 876-885.	13.9	2,026
5	Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2013, 369, 711-721.	13.9	2,001
6	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>American Journal of Gastroenterology</i> , 2015, 110, 1324-1338.	0.2	1,425
7	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2016, 375, 1946-1960.	13.9	1,316
8	Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. <i>Gut</i> , 2012, 61, 1693-1700.	6.1	1,295
9	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017, 376, 1723-1736.	13.9	1,232
10	Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. <i>Lancet, The</i> , 2008, 371, 660-667.	6.3	1,135
11	Certolizumab Pegol for the Treatment of Crohn's Disease. <i>New England Journal of Medicine</i> , 2007, 357, 228-238.	13.9	1,100
12	Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 1519-1528.	13.9	984
13	Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. <i>Gastroenterology</i> , 2004, 126, 402-413.	0.6	929
14	Methotrexate for the Treatment of Crohn's Disease. <i>New England Journal of Medicine</i> , 1995, 332, 292-297.	13.9	920
15	A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis. <i>Gastroenterology</i> , 2007, 132, 763-786.	0.6	917
16	Natalizumab Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2005, 353, 1912-1925.	13.9	880
17	Serious Infections and Mortality in Association With Therapies for Crohn's Disease: TREAT Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 621-630.	2.4	831
18	Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis. <i>Gastroenterology</i> , 2011, 141, 1194-1201.	0.6	792

#	ARTICLE	IF	CITATIONS
19	Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2014, 146, 85-95.	0.6	753
20	Treatment of Ulcerative Colitis with a Humanized Antibody to the $\alpha_4\beta_7$ Integrin. <i>New England Journal of Medicine</i> , 2005, 352, 2499-2507.	13.9	736
21	A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease. <i>Gastroenterology</i> , 2008, 135, 1130-1141.	0.6	709
22	A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease. <i>New England Journal of Medicine</i> , 2000, 342, 1627-1632.	13.9	704
23	Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. <i>Gastroenterology</i> , 1994, 106, 287-296.	0.6	688
24	Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREATâ„¢ Registry. <i>American Journal of Gastroenterology</i> , 2012, 107, 1409-1422.	0.2	652
25	The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i> , 2017, 66, 839-851.	6.1	630
26	Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. <i>Gastroenterology</i> , 2014, 147, 618-627.e3.	0.6	607
27	Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2014, 146, 96-109.e1.	0.6	605
28	A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. <i>Gastroenterology</i> , 2002, 122, 512-530.	0.6	598
29	Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial. <i>Gastroenterology</i> , 2007, 132, 1672-1683.	0.6	586
30	Oral Budesonide for Active Crohn's Disease. <i>New England Journal of Medicine</i> , 1994, 331, 836-841.	13.9	531
31	Development of the Crohn's disease digestive damage score, the Mann score. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1415-1422.	0.9	496
32	Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. <i>Gastroenterology</i> , 2000, 119, 1473-1482.	0.6	490
33	C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2015, 110, 802-819.	0.2	465
34	Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). <i>Gut</i> , 2012, 61, 535-542.	6.1	463
35	Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab. <i>Gastroenterology</i> , 2009, 137, 1250-1260.	0.6	440
36	Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 635-646.	2.3	432

#	ARTICLE	IF	CITATIONS
37	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2014, 384, 309-318.	6.3	421
38	Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1218-1224.	2.4	372
39	Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. <i>Lancet, The</i> , 2017, 389, 1699-1709.	6.3	364
40	Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2016, 374, 1754-1762.	13.9	361
41	Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity. <i>Gastroenterology</i> , 2013, 145, 987-995.	0.6	354
42	Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 1825-1834.	6.3	354
43	Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. <i>Gastroenterology</i> , 1999, 117, 49-57.	0.6	326
44	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. <i>Gastroenterology</i> , 2015, 148, 1035-1058.e3.	0.6	323
45	SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 489-501.e26.	0.5	316
46	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 348-354.e17.	2.4	309
47	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 1599-1607.	0.2	300
48	Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2014, 146, 681-688.e1.	0.6	294
49	Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. <i>Canadian Inflammatory Bowel Disease Study Group. Gastroenterology</i> , 1996, 110, 45-51.	0.6	284
50	Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the $\alpha 4\beta 7$ Integrin. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1370-1377.	2.4	283
51	Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2014, 147, 1296-1307.e5.	0.6	280
52	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. <i>Gut</i> , 2017, 66, 1049-1059.	6.1	274
53	Development and validation of a histological index for UC. <i>Gut</i> , 2017, 66, 50-58.	6.1	264
54	Low-Dose Cyclosporine for the Treatment of Crohn's Disease. <i>New England Journal of Medicine</i> , 1994, 330, 1846-1851.	13.9	256

#	ARTICLE	IF	CITATIONS
55	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	0.6	251
56	An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial. <i>Gastroenterology</i> , 2001, 120, 1330-1338.	0.6	250
57	Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2021, 385, 1280-1291.	13.9	243
58	Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1042-1050.e2.	2.4	240
59	The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. <i>Gut</i> , 2015, 64, 1539-1545.	6.1	239
60	Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. <i>Gastroenterology</i> , 1999, 117, 527-535.	0.6	236
61	Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. <i>Gastroenterology</i> , 2017, 153, 77-86.e6.	0.6	232
62	Inflammatory Bowel Disease: A Canadian Burden of Illness Review. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 811-817.	1.8	229
63	Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 188-202.	1.9	210
64	Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1470-1479.	0.9	205
65	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2016, 4, CD000543.	1.5	202
66	Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2006, 101, 1030-1038.	0.2	200
67	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2016, , CD000544.	1.5	197
68	The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 145, 149-157.e2.	0.6	196
69	Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1079-1087.	2.4	194
70	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2021, 397, 2372-2384.	6.3	194
71	Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 2123-2138.e8.	0.6	189
72	Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 233-242.	0.9	187

#	ARTICLE	IF	CITATIONS
73	Global burden of inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 2-3.	3.7	187
74	Converging Goals of Treatment of Inflammatory Bowel Disease From Clinical Trials and Practice. <i>Gastroenterology</i> , 2015, 148, 37-51.e1.	0.6	185
75	Annual cost of care for Crohn's disease: a payor perspective. <i>American Journal of Gastroenterology</i> , 2000, 95, 1955-1960.	0.2	179
76	Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. <i>Gut</i> , 2019, 68, 1115-1126.	6.1	178
77	Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1660-1671.	0.6	175
78	A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 654-666.	2.4	168
79	Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 325-334.	2.4	165
80	Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 229-239.e5.	2.4	164
81	Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT _{CD} Registry. <i>American Journal of Gastroenterology</i> , 2014, 109, 212-223.	0.2	160
82	A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 77-86.	1.9	160
83	The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients. <i>American Journal of Gastroenterology</i> , 2007, 102, 794-802.	0.2	157
84	An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 347-357.	1.9	157
85	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. <i>Gut</i> , 2016, 65, 1447-1455.	6.1	155
86	IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 23-32.	0.6	149
87	Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. <i>Gut</i> , 2015, 64, 77-83.	6.1	145
88	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 1007-1018.e7.	0.6	145
89	CDP571, a humanised monoclonal antibody to tumour necrosis factor α , for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. <i>Gut</i> , 2004, 53, 1485-1493.	6.1	144
90	Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 473-479.	0.5	143

#	ARTICLE	IF	CITATIONS
91	Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 670-678.e3.	2.4	142
92	Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements. <i>American Journal of Gastroenterology</i> , 2012, 107, 179-194.	0.2	142
93	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw176.	0.6	141
94	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw177.	0.6	140
95	The challenge of indication extrapolation for infliximab biosimilars. <i>Biologics</i> , 2014, 42, 177-183.	0.5	138
96	Association Between Response to Etrolizumab and Expression of Integrin α 4 and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 477-487.e9.	0.6	133
97	Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. <i>Gut</i> , 2006, 55, 1568-1574.	6.1	131
98	Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 921-929.	0.6	130
99	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 537-549.e10.	0.6	130
100	Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 65-77.	1.9	128
101	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 671-680.	3.7	126
102	Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. <i>Lancet</i> , 2022, 399, 2015-2030.	6.3	126
103	Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 1045-1058.	0.6	125
104	A Randomized Study Comparing a Patient-Directed Hypertension Management Strategy With Usual Office-Based Care. <i>American Journal of Hypertension</i> , 1997, 10, 58-67.	1.0	121
105	Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2031-2045.e11.	2.4	121
106	Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. <i>Gut</i> , 2017, 66, 588-596.	6.1	117
107	Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1200-1210.	1.9	115
108	Methotrexate for induction of remission in refractory Crohn's disease. <i>The Cochrane Library</i> , 2015, CD003459.	1.5	113

#	ARTICLE	IF	CITATIONS
109	Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 349-358.	0.9	110
110	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018, 67, 244-254.	6.1	108
111	Systematic review: the effectiveness of budesonide therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1509-1517.	1.9	107
112	Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. <i>Lancet</i> , The, 2022, 399, 2031-2046.	6.3	105
113	Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 1032-1041.	1.9	104
114	Histologic Evaluation of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 564-575.	0.9	102
115	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease—an International, Cross-disciplinary Consensus. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 408-418.	0.6	102
116	Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1879-1892.	2.4	101
117	Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 159, 1262-1275.e7.	0.6	101
118	Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 35-46.	0.6	100
119	Long-term safety of vedolizumab for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1353-1365.	1.9	97
120	Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 447-459.	1.9	96
121	Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1158-1169.	0.6	95
122	Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 819-828.	3.7	95
123	Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 578-590.e4.	2.4	94
124	Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process. <i>American Journal of Gastroenterology</i> , 2012, 107, 1770-1776.	0.2	93
125	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 687-695.e10.	0.6	93
126	A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1126-1135.	1.9	90

#	ARTICLE	IF	CITATIONS
127	Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. <i>Gastroenterology</i> , 2022, 162, 1650-1664.e8.	0.6	88
128	A Multicenter, Randomized, Double-Blind Trial of Everolimus Versus Azathioprine and Placebo to Maintain Steroid-Induced Remission in Patients With Moderate-to-Severe Active Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 2284-2292.	0.2	87
129	Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives. <i>Current Gastroenterology Reports</i> , 2014, 16, 378.	1.1	86
130	Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1170-1181.	1.9	86
131	Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 674-688.	1.9	84
132	An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). <i>Gastroenterology</i> , 2000, 118, A874.	0.6	81
133	Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest. <i>Gastroenterology</i> , 2017, 152, S1308-S1309.	0.6	77
134	Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 621-626.	0.6	77
135	The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 105-119.	0.6	76
136	Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 130-138.e7.	2.4	76
137	Assessment of mucosal healing in inflammatory bowel disease: review. <i>Gastrointestinal Endoscopy</i> , 2015, 82, 246-255.	0.5	74
138	Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. <i>Gut</i> , 2016, 65, 1119-1125.	6.1	74
139	Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1691-1699.	0.9	73
140	Briakinumab for Treatment of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	67
141	Reproducibility of histological assessments of disease activity in UC. <i>Gut</i> , 2015, 64, 1765-1773.	6.1	66
142	A phase II study of laquinimod in Crohn's disease. <i>Gut</i> , 2015, 64, 1227-1235.	6.1	66
143	Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 5-23.	1.9	66
144	Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 994-1007.	0.9	66

#	ARTICLE	IF	CITATIONS
145	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2018, 16, 129-146.	0.3	64
146	Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Alimentary Pharmacology and Therapeutics, 2019, 49, 31-40.	1.9	64
147	Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2015, 42, 504-514.	1.9	63
148	Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2018, 63, 825-833.	1.1	62
149	Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. Journal of Crohn's and Colitis, 2019, 13, 50-57.	0.6	61
150	Vedolizumab for Induction and Maintenance of Remission in Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 1151-1159.	0.9	60
151	Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. Gastroenterology, 2018, 154, 61-64.e6.	0.6	59
152	Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. Journal of Crohn's and Colitis, 2021, 15, 1120-1129.	0.6	59
153	Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. Gastroenterology, 2019, 157, 1233-1244.e5.	0.6	58
154	Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease. BioDrugs, 2020, 34, 713-721.	2.2	58
155	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology, 2021, 160, 2291-2302.	0.6	57
156	A Systematic Review of Measurement of Endoscopic Disease Activity and Mucosal Healing in Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 1850-1861.	0.9	56
157	Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. American Journal of Gastroenterology, 2020, 115, 738-745.	0.2	56
158	Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews. Inflammatory Bowel Diseases, 2013, 19, 1.	0.9	55
159	Cost-effectiveness analysis of arthroscopic surgery compared with non-operative management for osteoarthritis of the knee. BMJ Open, 2016, 6, e009949.	0.8	54
160	Review article: Drug development in inflammatory bowel disease: budesonide—a model of targeted therapy. Alimentary Pharmacology and Therapeutics, 1997, 11, 98-108.	1.9	53
161	Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2016, 44, 157-169.	1.9	53
162	The development of a magnetic resonance imaging index for fistulising Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 516-528.	1.9	53

#	ARTICLE	IF	CITATIONS
163	Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 1019-1031.e7.	0.6	52
164	Reliability of histologic assessment in patients with eosinophilic oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 940-950.	1.9	51
165	Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. <i>American Journal of Gastroenterology</i> , 2018, 113, 1678-1688.	0.2	51
166	Innovations in Oral Therapies for Inflammatory Bowel Disease. <i>Drugs</i> , 2019, 79, 1321-1335.	4.9	51
167	Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2014, 109, 994-1004.	0.2	50
168	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 607-616.	0.6	50
169	Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review. <i>Gastroenterology</i> , 2020, 158, 137-150.e1.	0.6	50
170	Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Gut</i> , 2009, 58, 1354-1362.	6.1	49
171	Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1158-1169.	1.9	49
172	Etolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 118-127.	3.7	49
173	Health-Related Quality of Life During Natalizumab Maintenance Therapy for Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2007, 102, 2737-2746.	0.2	48
174	Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 162, 26-31.	0.6	48
175	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	2.4	48
176	Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 440-449.	0.9	47
177	5-ASA therapy for active Crohn's disease: Old friends, old data, and a new conclusion. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 376-378.	2.4	46
178	Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. <i>Gut</i> , 2019, 68, 1162-1168.	6.1	45
179	Etolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 128-140.	3.7	45
180	Therapeutics and inflammatory bowel disease: A guide to the interpretation of randomized controlled trials. <i>Gastroenterology</i> , 1996, 110, 275-283.	0.6	44

#	ARTICLE	IF	CITATIONS
181	Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. Journal of Crohn's and Colitis, 2018, 12, 167-177.	0.6	44
182	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology, 2018, 16, 637-647.e13.	2.4	44
183	CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology and Therapeutics, 2006, 23, 617-628.	1.9	43
184	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Alimentary Pharmacology and Therapeutics, 2017, 45, 1058-1072.	1.9	43
185	Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. American Journal of Gastroenterology, 2017, 112, 1658-1669.	0.2	43
186	Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 873-886.	1.9	43
187	Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 351-366.	8.2	43
188	Histologic scoring indices for evaluation of disease activity in ulcerative colitis. The Cochrane Library, 2017, 2017, CD011256.	1.5	42
189	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology, 2019, 114, 733-745.	0.2	42
190	T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects. Drugs, 2014, 74, 297-311.	4.9	41
191	Assessment of Histologic Disease Activity in Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 2092-2103.	0.9	41
192	Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1021-1042.	1.9	41
193	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clinical Gastroenterology and Hepatology, 2018, 16, 1407-1419.e22.	2.4	41
194	Clinically Meaningful Improvement in Health-Related Quality of Life in a Randomized Controlled Trial of Certolizumab Pegol Maintenance Therapy for Crohn's Disease. American Journal of Gastroenterology, 2009, 104, 1976-1983.	0.2	40
195	Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Alimentary Pharmacology and Therapeutics, 2011, 33, 541-550.	1.9	40
196	No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. American Journal of Gastroenterology, 2018, 113, 1197-1205.	0.2	40
197	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). Journal of Allergy and Clinical Immunology, 2022, 149, 659-670.	1.5	40
198	Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human) Tj ETQq0 0 0 rgBT /Overlock 10 Inflammatory Bowel Diseases, 2010, 16, 1708-1716.	0.9	39

#	ARTICLE	IF	CITATIONS
199	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 607-618.	0.6	39
200	Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised <sc>GEMINI</sc> 1 trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 264-275.	1.9	39
201	Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 1584-1592.	0.2	37
202	Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 28-37.	3.7	37
203	566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2012, 142, S-114.	0.6	36
204	The safety of vedolizumab for the treatment of ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 501-507.	1.0	35
205	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>BMJ Open</i> , 2017, 7, e016146.	0.8	35
206	A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 373-384.	1.9	34
207	Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. <i>Gut</i> , 2018, 67, 61-69.	6.1	34
208	Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. <i>Drugs</i> , 2017, 77, 363-377.	4.9	33
209	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1714-1729.e3.	2.4	33
210	Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1047-1066.	1.9	33
211	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1578-1596.	1.9	31
212	Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 105-115.e14.	2.4	31
213	Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases. <i>Physiological Reviews</i> , 2022, 102, 605-652.	13.1	31
214	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 553-564.	1.9	30
215	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2020, 2020, CD000544.	1.5	30
216	565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD). <i>Gastroenterology</i> , 2012, 142, S-114.	0.6	29

#	ARTICLE	IF	CITATIONS
217	Randomised non-inferiority trial: 1600Âmg versus 400Âmg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 292-302.	1.9	29
218	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 360-369.e2.	0.5	29
219	International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease. <i>Gut</i> , 2022, 71, 479-486.	6.1	29
220	Overview of Subsequent Entry Biologics for the Management of Inflammatory Bowel Disease and Canadian Association of Gastroenterology Position Statement on Subsequent Entry Biologics. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013, 27, 567-571.	1.8	28
221	IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101604.	1.0	28
222	Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1100-1111.	1.9	27
223	Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1086-1093.	1.9	27
224	Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1008-1016.	1.9	27
225	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2500-2509.e1.	2.4	27
226	Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2001-2010.	0.6	27
227	Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	26
228	Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1006-1014.	0.6	26
229	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 435-445.	1.9	26
230	Systematic review: medical therapy for fibrostenosing Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1233-1246.	1.9	26
231	Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1201-1216.	0.6	25
232	The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. <i>Advances in Therapy</i> , 2020, 37, 4491-4518.	1.3	25
233	Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 817-846.e10.	2.4	25
234	Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1188-1194.	1.9	24

#	ARTICLE	IF	CITATIONS
235	OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i042-i043.	0.6	24
236	Alicaforsen for the treatment of inflammatory bowel disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 991-997.	1.9	23
237	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1760-1768.e1.	2.4	22
238	Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2020, 2020, CD000543.	1.5	22
239	Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. <i>Drugs</i> , 2021, 81, 333-347.	4.9	22
240	Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1401-1409.	1.9	21
241	DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S42-S43.	0.6	19
242	Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 987-997.	1.0	19
243	Efficient Early Drug Development for Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 1056-1060.	0.6	19
244	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 246-255.	0.6	19
245	882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study. <i>Gastroenterology</i> , 2018, 154, S-1360-S-1361.	0.6	19
246	Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 649-660.	1.9	19
247	What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101602.	1.0	19
248	Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1121-1132.e2.	2.4	18
249	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 784-793.	1.9	18
250	Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1 α stabiliser, for treatment of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 401-411.	1.9	18
251	Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. <i>Biologicals</i> , 2012, 40, 517-527.	0.5	17
252	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 304-313.	0.9	17

#	ARTICLE	IF	CITATIONS
253	Benefitâ€“Risk Assessment of Vedolizumab in the Treatment of Crohnâ€™s Disease and Ulcerative Colitis. <i>Drug Safety</i> , 2019, 42, 617-632.	1.4	17
254	Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohnâ€™s Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2139-2141.e2.	2.4	17
255	The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohnâ€™s Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 883-895.	0.6	16
256	Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. <i>Gastroenterology</i> , 2020, 159, 2013-2018.e7.	0.6	16
257	Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 727-736.e2.	2.4	16
258	S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2010, 138, S-167-S-168.	0.6	15
259	A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 63-70.	3.7	15
260	Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 424-431.e7.	2.4	15
261	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. <i>American Journal of Gastroenterology</i> , 2020, 115, 885-894.	0.2	15
262	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.	3.6	15
263	Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1047-1056.	0.9	14
264	Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderateâ€“Severe Ulcerative Colitis and Crohnâ€™s Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 515-523.	0.9	14
265	Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis. <i>Scientific Reports</i> , 2021, 11, 18243.	1.6	14
266	Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis. <i>Pharmacotherapy</i> , 2015, 35, 412-423.	1.2	13
267	Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. <i>The Cochrane Library</i> , 2017, 9, CD011572.	1.5	13
268	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , 2022, 117, 264-271.	0.2	13
269	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1108-1117.	1.9	13
270	P-140â€™s Pharmacokinetic/Pharmacodynamic Relationship and Immunogenicity of Vedolizumab in Adults with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, S80.	0.9	12

#	ARTICLE	IF	CITATIONS
271	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 114-126.	1.9	12
272	Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2555-2563.	1.1	12
273	Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: <sc>ERELATE</sc> Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 463-476.	1.9	12
274	Ozanimod Treatment for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2016, 375, e17.	13.9	11
275	OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i025-i026.	0.6	11
276	Antibiotics for induction and maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2017, , .	1.5	10
277	OP023 A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn's disease (CD). <i>Journal of Crohn's and Colitis</i> , 2018, 12, S016-S017.	0.6	10
278	Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2519-2528.	1.1	10
279	OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S024-S025.	0.6	10
280	Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2598-2606.	2.4	10
281	The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1619-1623.	0.9	9
282	Alternative and Complementary Approaches for the Treatment of Inflammatory Bowel Disease: Evidence From Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 843-851.	0.9	9
283	Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 224-243.	0.6	9
284	Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 717-736.	0.6	9
285	Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. <i>Intestinal Research</i> , 2023, 21, 110-125.	1.0	9
286	The Next Wave of Biological Agents for the Treatment of IBD. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1737-1743.	0.9	8
287	Briakinumab (Anti-interleukin 12/23p40, ABT874) for Treatment of Crohn's Disease (CD). <i>American Journal of Gastroenterology</i> , 2010, 105, S457-S458.	0.2	8
288	1053 Early Combined Immunosuppression for the Management of Crohn's Disease: A Community-Based Cluster Randomized Trial. <i>Gastroenterology</i> , 2014, 146, S-187.	0.6	7

#	ARTICLE	IF	CITATIONS
289	The Evolution of Treatment Paradigms in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 661-677.	1.0	7
290	Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. <i>Gastroenterology</i> , 2017, 152, S602.	0.6	7
291	Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 279-288.	1.0	7
292	Portal Hypertensive Bleeding. , 0, , 453-485.		7
293	Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 793-801.	1.5	6
294	Adalimumab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 2020, 2020, CD012877.	1.5	6
295	Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e750-e760.	2.4	6
296	Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 178-190.	1.9	6
297	Infliximab in the Treatment of Crohn's Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2000, 14, 6C-6C.	1.8	5
298	P592 A phase 1, double-blind placebo-controlled single-dose study to determine the immune response to systemic and mucosal antigenic challenge in the presence of vedolizumab. <i>Journal of Crohn's and Colitis</i> , 2013, 7, S248.	0.6	5
299	Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2155-2164.	0.9	5
300	P661 Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn's disease in the STEPSTONE trial. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S450-S450.	0.6	5
301	Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 639-646.	0.9	5
302	Ogilvie's Syndrome. , 0, , 303-309.		5
303	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1574-1582.	1.9	5
304	Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. <i>Current Treatment Options in Gastroenterology</i> , 2014, 12, 76-89.	0.3	4
305	Effect of Vedolizumab Treatment on Extraintestinal Manifestations in Patients with Crohn's Disease: A Gemini 2 Post hoc Analysis. <i>Gastroenterology</i> , 2017, 152, S597.	0.6	4
306	Efficacy and Safety of Open-Label Maintenance Therapy with Subcutaneous Risankizumab in Patients with Moderately-Severe Crohn's Disease. <i>Gastroenterology</i> , 2017, 152, S1310.	0.6	4

#	ARTICLE	IF	CITATIONS
307	Editorial: treating strictures in inflammatory bowel disease—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1313-1314.	1.9	4
308	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1128-1155.	1.1	4
309	Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, S371.	0.2	4
310	A Saudi Gastroenterology association position statement on the use of tumor necrosis factor- α antagonists for the treatment of inflammatory bowel disease. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 185.	0.5	4
311	Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1442-1453.	1.9	4
312	Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT. <i>Clinical Gastroenterology and Hepatology</i> , 2020, , .	2.4	4
313	Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 447-454.e1.	2.4	4
314	Design of Clinical Trials for Mild to Moderate Ulcerative Colitis. <i>Gastroenterology</i> , 2022, 162, 1005-1018.	0.6	4
315	Vedolizumab Induction Therapy for Patients With Crohn's Disease and Prior Anti-TNF Antagonist Failure: A Randomized, Placebo-controlled, Double-blind, Multicenter Trial. <i>Inflammatory Bowel Diseases</i> , 2012, 18, S24-S25.	0.9	3
316	New Applications for Traditional Drugs in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2948-2957.	0.9	3
317	Vedolizumab for the treatment of inflammatory bowel diseases. <i>Clinical Investigation</i> , 2015, 5, 247-255.	0.0	3
318	Emerging Therapies for Inflammatory Bowel Diseases. <i>Digestive Diseases</i> , 2016, 34, 67-73.	0.8	3
319	Sa1937 Exposure-Response Relationship for Certolizumab Pegol During the Induction Phase in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2016, 150, S409.	0.6	3
320	Infliximab for maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , 0, , .	1.5	3
321	Evaluation of the effect of storage condition on cell extraction and flow cytometric analysis from intestinal biopsies. <i>Journal of Immunological Methods</i> , 2018, 459, 50-54.	0.6	3
322	Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 364-374.	1.9	3
323	Identifying Outcomes in Clinical Trials of Pouchitis for the Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1637-1640.	2.4	3
324	Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 15-32.	0.3	3

#	ARTICLE	IF	CITATIONS
325	The role of imaging in determining prognosis for primary sclerosing cholangitis: A systematic review. Saudi Journal of Gastroenterology, 2019, 25, 152.	0.5	3
326	Update on Tofacitinib for Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2016, 12, 572-574.	0.2	3
327	Natalizumab reduces the rate of hospitalization in moderate to severe Crohn's Patients: Evidence from the Clinical Trial Program. Inflammatory Bowel Diseases, 2009, 15, S27.	0.9	2
328	Baseline Corticosteroid Use and Corticosteroid-Free Clinical Remission in Crohn's Disease Patients Treated With Certolizumab Pegol in the PRECiSE 2 Trial. Inflammatory Bowel Diseases, 2012, 18, S23-S24.	0.9	2
329	Adalimumab for maintenance of remission in Crohn's disease. The Cochrane Library, 0, , .	1.5	2
330	Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (<sc>EOE</sc>â€‹<sc>HSS</sc>)â€‹”an important first step. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1714-1715.	1.9	2
331	Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions. Current Treatment Options in Gastroenterology, 2020, 18, 442-461.	0.3	2
332	Routine incorporation of the local read in Crohn's disease clinical trials? Not so fast. Gastrointestinal Endoscopy, 2021, 93, 183-186.	0.5	2
333	Safety and Positioning of Vedolizumab in Patients With Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2018, 14, 244-246.	0.2	2
334	Adalimumab Induction Dose Reduces Hospitalization Risk in Patients With Ulcerative Colitis During the First 8 Weeks of Therapy. Inflammatory Bowel Diseases, 2012, 18, S40-S41.	0.9	1
335	Combination therapy for the treatment of Crohn's disease. Expert Opinion on Biological Therapy, 2015, 15, 1429-1442.	1.4	1
336	Editorial: the impact of the placebo effect in Crohn's disease â€‹” author's reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1472-1472.	1.9	1
337	Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews. Inflammatory Bowel Diseases, 2019, 25, 472-478.	0.9	1
338	Editorial: histologic normalisation in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 399-401.	1.9	1
339	Medical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews. Inflammatory Bowel Diseases, 2021, 27, 1513-1524.	0.9	1
340	Clostridium Difficile Disease. , 0, , 285-301.		1
341	Ascites, Hepatorenal Syndrome, and Spontaneous Bacterial Peritonitis. , 0, , 487-503.		1
342	Non-Variceal Gastrointestinal Hemorrhage. , 0, , 139-159.		1

#	ARTICLE	IF	CITATIONS
343	Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2014, 10, 478-489.	0.2	1
344	Updates in Clinical, Endoscopic, and Histologic Composite and Co-primary Endpoints for Clinical Trials in Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 608.	0.3	1
345	Colorectal Cancer in Ulcerative Colitis: Surveillance. , 0, , 247-253.		1
346	Design of Clinical Trials for Mild to Moderate Crohn's Disease. <i>Gastroenterology</i> , 2022, , .	0.6	1
347	Gallstone Disease. , 0, , 311-320.		1
348	Liver Transplantation: Prevention and Treatment of Infection. , 0, , 573-586.		1
349	The Relationship Between Plasma Concentrations of Certolizumab Pegol and Clinical Efficacy: Results From the PRECISE 2 Trial. <i>Inflammatory Bowel Diseases</i> , 2012, 18, S23.	0.9	0
350	Letter: limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 121-122.	1.9	0
351	Reply. <i>Gastroenterology</i> , 2016, 150, 1041-1042.	0.6	0
352	Editorial: aminosalicylates in Crohn's disease—prevalence, risks, costs and time to reassess? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 489-489.	1.9	0
353	Editorial: evolving histological assessment of NASH. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1245-1246.	1.9	0
354	P185 A comparison of early response parameters to inform a treat-to-target approach in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S231-S231.	0.6	0
355	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. <i>Gastroenterology</i> , 2021, 161, 778-784.	0.6	0
356	Anti-adhesion strategies for inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , 2010, 6, 372-4.	0.2	0
357	Benefits, Concerns, and Future Directions of Biosimilars in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2017, 13, 745-747.	0.2	0
358	Review of the Landmark VARSITY Trial. <i>Gastroenterology and Hepatology</i> , 2021, 17, 330-332.	0.2	0
359	P700 The GEM Project: Stool metabolomic profile is associated with microbiome risk score and with future onset of Crohn's disease in healthy first-degree relatives. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i596-i597.	0.6	0
360	Pouchitis After Restorative Proctocolectomy. , 0, , 211-219.		0

#	ARTICLE	IF	CITATIONS
361	Barrett's Esophagus. , 0, , 55-68.		0
362	Liver Transplantation: Prevention and Treatment of Rejection. , 0, , 545-571.		0
363	Management of Hepatitis B and C After Liver Transplantation. , 0, , 587-601.		0
364	Esophageal Motility Disorders: Achalasia and Spastic Motor Disorders. , 0, , 69-81.		0
365	Functional Dyspepsia. , 0, , 161-168.		0
366	Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitisâ€”authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 957-958.	1.9	0
367	Development and Validation of a Digital Analysis Method to Quantify CD3-immunostained T Lymphocytes in Whole Slide Images of Crohn's Disease Biopsies. Applied Immunohistochemistry and Molecular Morphology, 2022, Publish Ahead of Print, .	0.6	0
368	Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease.. Gastroenterology and Hepatology, 2022, 18, 14-27.	0.2	0
369	Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials. Inflammatory Bowel Diseases, 0, , .	0.9	0